MehmoodHussainHashmiMD

Oncology • Topeka, KS

Hematologic Oncology

Executive Director Oncology Service Line

Join to view full profile

Dr. Hashmi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hashmi's full profile

Already have an account?

Office
1414 Sw 8th Ave
Topeka, KS 66606
Phone+1 785-354-5300

Fax+1 785-354-5309

Education & Training

Carnegie Mellon UniversityMasters in Medical Management, 2018 - 2020
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 2001 - 2004
Dow University of Health SciencesClass of 1998

Certifications & Licensure

KS State Medical License 2007 - 2025
OK State Medical License 2003 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

3 citations
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasect...
Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins
Journal of Clinical Oncology. 2024-06-10
2 citations
Impaired microvascular reactivity in patients treated with 5-fluorouracil chemotherapy regimens: Potential role of endothelial dysfunction.
Stephen T Hammond, Dryden R Baumfalk, Shannon K Parr, Alec L E Butenas, Britton C Scheuermann
International Journal of Cardiology. Heart & Vasculature. 2023-12-01
5 citations
Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.
Smita Mehta, James C. Moon, Mehmood Hashmi, Michael LeBlanc, Chao Hui Huang
Oncology Reports. 2013-06-01

Press Mentions

Stormont Vail Cultural Ambassadors Uphold Small Moments Culture in HospitalsAugust 26th, 2020